FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2061869884> ?p ?o ?g. }

• W2061869884 endingPage "265" @default.
• W2061869884 startingPage "259" @default.
• W2061869884 abstract "Background Nasal immunotherapy with single allergen extracts, following premedicaton with cromolyn, has been reported to be effective in treating seasonal and perennial allergic rhinitis. Methods We conducted a double-blind, placebo-controlled study to assess the efficacy, tolerability, and mechanism of action of nasal immunotherapy for allergic rhinitis caused by weed pollens from three unrelated families. Twenty-seven weed-allergic patients underwent baseline nasal provocation and titrated skin test with a mixed weed extract containing ragweed, sage, and Chenopod extracts. Patients were randomized to receive either mixed weed extract or placebo. Nasal immunotherapy was self-administered daily to alternate nostrils preceded by 5.2 mg intranasal cromolyn. Beginning with 1:2500 wt/vol, the concentration was increased to 1:10 wt /vol over an average period of 36 days. The maintenance dose (1:10 wt/vol) was administered daily for 12 to 16 weeks through the weed pollen season. Patients recorded nasal and eye symptoms and the use of rescue medications throughout the study. A nasal lavage for cytokine levels and nasal scraping with Rhinoprobe for nasal cytology were performed at the peak of the weed season. Nasal provocation and titrated skin tests with mixed weed extract were repeated after the weed season. Nasal lavage and scraping were also performed before and 24 hours after the final nasal provocation. Results During the peak weeks of the weed season the group receiving mixed weed extract by nasal instillation, compared with those treated with placebo, had significantly lower total nasal symptom scores, total eye symptom scores, and symptom medication scores. There were no significant differences in the nasal cytology or cytokines levels between the two groups, except for elevated IL-10 in the nasal lavage in the treated group at the peak of the season. Nasal symptoms and medication use were higher preseasonally in the active treatment group. Conclusion Nasal immunotherapy with aqueous mixed weed extract administered with cromolyn sodium pretreatment for 17 to 21 weeks was effective in reducing both nasal and ocular symptoms of weed pollen-induced allergic rhinitis. There were increased nasal symptoms in the treated group preseasonally. Nasal immunotherapy with single allergen extracts, following premedicaton with cromolyn, has been reported to be effective in treating seasonal and perennial allergic rhinitis. We conducted a double-blind, placebo-controlled study to assess the efficacy, tolerability, and mechanism of action of nasal immunotherapy for allergic rhinitis caused by weed pollens from three unrelated families. Twenty-seven weed-allergic patients underwent baseline nasal provocation and titrated skin test with a mixed weed extract containing ragweed, sage, and Chenopod extracts. Patients were randomized to receive either mixed weed extract or placebo. Nasal immunotherapy was self-administered daily to alternate nostrils preceded by 5.2 mg intranasal cromolyn. Beginning with 1:2500 wt/vol, the concentration was increased to 1:10 wt /vol over an average period of 36 days. The maintenance dose (1:10 wt/vol) was administered daily for 12 to 16 weeks through the weed pollen season. Patients recorded nasal and eye symptoms and the use of rescue medications throughout the study. A nasal lavage for cytokine levels and nasal scraping with Rhinoprobe for nasal cytology were performed at the peak of the weed season. Nasal provocation and titrated skin tests with mixed weed extract were repeated after the weed season. Nasal lavage and scraping were also performed before and 24 hours after the final nasal provocation. During the peak weeks of the weed season the group receiving mixed weed extract by nasal instillation, compared with those treated with placebo, had significantly lower total nasal symptom scores, total eye symptom scores, and symptom medication scores. There were no significant differences in the nasal cytology or cytokines levels between the two groups, except for elevated IL-10 in the nasal lavage in the treated group at the peak of the season. Nasal symptoms and medication use were higher preseasonally in the active treatment group. Nasal immunotherapy with aqueous mixed weed extract administered with cromolyn sodium pretreatment for 17 to 21 weeks was effective in reducing both nasal and ocular symptoms of weed pollen-induced allergic rhinitis. There were increased nasal symptoms in the treated group preseasonally." @default.
• W2061869884 created "2016-06-24" @default.
• W2061869884 creator A5000832941 @default.
• W2061869884 creator A5016274246 @default.
• W2061869884 creator A5021609170 @default.
• W2061869884 creator A5027812995 @default.
• W2061869884 creator A5063948687 @default.
• W2061869884 creator A5076639428 @default.
• W2061869884 date "1997-09-01" @default.
• W2061869884 modified "2023-09-27" @default.
• W2061869884 title "Nasal Immunotherapy in Weed-Induced Allergic Rhinitis" @default.
• W2061869884 cites W1503200131 @default.
• W2061869884 cites W1510730676 @default.
• W2061869884 cites W1517658874 @default.
• W2061869884 cites W1570159316 @default.
• W2061869884 cites W1572210960 @default.
• W2061869884 cites W1573470869 @default.
• W2061869884 cites W1607246759 @default.
• W2061869884 cites W1986829895 @default.
• W2061869884 cites W2009754477 @default.
• W2061869884 cites W2012967235 @default.
• W2061869884 cites W2034108972 @default.
• W2061869884 cites W2045756352 @default.
• W2061869884 cites W2055773200 @default.
• W2061869884 cites W2071054546 @default.
• W2061869884 cites W2071357739 @default.
• W2061869884 cites W2071624788 @default.
• W2061869884 cites W2084990572 @default.
• W2061869884 cites W2089658906 @default.
• W2061869884 cites W2092025680 @default.
• W2061869884 cites W2093221306 @default.
• W2061869884 cites W2101771134 @default.
• W2061869884 cites W2106694501 @default.
• W2061869884 cites W2115954882 @default.
• W2061869884 cites W2124871577 @default.
• W2061869884 cites W2150195134 @default.
• W2061869884 cites W2155896510 @default.
• W2061869884 cites W2158860741 @default.
• W2061869884 cites W2168242801 @default.
• W2061869884 cites W2191654227 @default.
• W2061869884 doi "https://doi.org/10.1016/s1081-1206(10)63012-8" @default.
• W2061869884 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/9305235" @default.
• W2061869884 hasPublicationYear "1997" @default.
• W2061869884 type Work @default.
• W2061869884 sameAs 2061869884 @default.
• W2061869884 citedByCount "38" @default.
• W2061869884 countsByYear W20618698842018 @default.
• W2061869884 countsByYear W20618698842020 @default.
• W2061869884 countsByYear W20618698842022 @default.
• W2061869884 crossrefType "journal-article" @default.
• W2061869884 hasAuthorship W2061869884A5000832941 @default.
• W2061869884 hasAuthorship W2061869884A5016274246 @default.
• W2061869884 hasAuthorship W2061869884A5021609170 @default.
• W2061869884 hasAuthorship W2061869884A5027812995 @default.
• W2061869884 hasAuthorship W2061869884A5063948687 @default.
• W2061869884 hasAuthorship W2061869884A5076639428 @default.
• W2061869884 hasConcept C110586980 @default.
• W2061869884 hasConcept C126322002 @default.
• W2061869884 hasConcept C142724271 @default.
• W2061869884 hasConcept C197934379 @default.
• W2061869884 hasConcept C203014093 @default.
• W2061869884 hasConcept C204787440 @default.
• W2061869884 hasConcept C207480886 @default.
• W2061869884 hasConcept C27081682 @default.
• W2061869884 hasConcept C2775891814 @default.
• W2061869884 hasConcept C2776472760 @default.
• W2061869884 hasConcept C2778375690 @default.
• W2061869884 hasConcept C2780510475 @default.
• W2061869884 hasConcept C2780931586 @default.
• W2061869884 hasConcept C42219234 @default.
• W2061869884 hasConcept C6557445 @default.
• W2061869884 hasConcept C71924100 @default.
• W2061869884 hasConcept C85663871 @default.
• W2061869884 hasConcept C86803240 @default.
• W2061869884 hasConceptScore W2061869884C110586980 @default.
• W2061869884 hasConceptScore W2061869884C126322002 @default.
• W2061869884 hasConceptScore W2061869884C142724271 @default.
• W2061869884 hasConceptScore W2061869884C197934379 @default.
• W2061869884 hasConceptScore W2061869884C203014093 @default.
• W2061869884 hasConceptScore W2061869884C204787440 @default.
• W2061869884 hasConceptScore W2061869884C207480886 @default.
• W2061869884 hasConceptScore W2061869884C27081682 @default.
• W2061869884 hasConceptScore W2061869884C2775891814 @default.
• W2061869884 hasConceptScore W2061869884C2776472760 @default.
• W2061869884 hasConceptScore W2061869884C2778375690 @default.
• W2061869884 hasConceptScore W2061869884C2780510475 @default.
• W2061869884 hasConceptScore W2061869884C2780931586 @default.
• W2061869884 hasConceptScore W2061869884C42219234 @default.
• W2061869884 hasConceptScore W2061869884C6557445 @default.
• W2061869884 hasConceptScore W2061869884C71924100 @default.
• W2061869884 hasConceptScore W2061869884C85663871 @default.
• W2061869884 hasConceptScore W2061869884C86803240 @default.
• W2061869884 hasIssue "3" @default.
• W2061869884 hasLocation W20618698841 @default.
• W2061869884 hasLocation W20618698842 @default.
• W2061869884 hasOpenAccess W2061869884 @default.
• W2061869884 hasPrimaryLocation W20618698841 @default.
• W2061869884 hasRelatedWork W2033068352 @default.

• next